JNK1 determines the oncogenic or tumor-suppressive activity of the integrin-linked kinase in human rhabdomyosarcoma

Journal of Clinical Investigation

Volumn 119, Issue 6, 2009, Pages 1558-1570

  Durbin, Adam D ^a,b,c   Somers, Gino R ^a,c   Forrester, Michael ^c   Pienkowska, Malgorzata ^c   Hannigan, Gregory E ^d   Malkin, David ^a,c  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c HOSPITAL FOR SICK CHILDREN   (Canada)

^d HUDSON INSTITUTE OF MEDICAL RESEARCH   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

INTEGRIN LINKED KINASE; STRESS ACTIVATED PROTEIN KINASE 1; TRANSCRIPTION FACTOR FKHR; TRANSCRIPTION FACTOR PAX3;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; EMBRYONAL RHABDOMYOSARCOMA; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; MOUSE; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RHABDOMYOSARCOMA;

ANIMALS; ENZYME ACTIVATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE; MICE, NUDE; MITOGEN-ACTIVATED PROTEIN KINASE 8; ONCOGENE PROTEINS; ONCOGENE PROTEINS, FUSION; PROTEIN-SERINE-THREONINE KINASES; RHABDOMYOSARCOMA; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; SURVIVAL RATE; TUMOR SUPPRESSOR PROTEINS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 67651006358     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI37958     Document Type: Article

References (46)

1. Breneman, J.C., et al. 2003. Prognostic factors and clinical outcomes in children and adolescents with metastatic rhabdomyosarcoma - a report from the Intergroup Rhabdomyosarcoma Study IV. J. Clin. Oncol. 21:78-84.
2. Wexler, L.H., Crist, W.M., and Helman, L.J. 2002. Rhabdomyosarcoma and the undifferentiated sarcomas. In Principles and practice of pediatric oncology. 4th edition. P.A. Pizzo and D.G. Poplack, editors. Lippincott Williams & Wilkins. Philadelphia, Pennsylvania, USA. 939-971.
3. Davicioni, E., et al. 2006. Identification of a PAXFKHR gene expression signature that defines molecular classes and determines the prognosis of alveolar rhabdomyosarcomas. Cancer Res. 66:6936-6946.
4. Karnik, P., et al. 1998. Two distinct tumor suppressor loci within chromosome 11p15 implicated in breast cancer progression and metastasis. Hum. Mol. Genet. 7:895-903.
5. Hannigan, G.E., et al. 1996. Regulation of cell adhesion and anchorage-dependent growth by a new beta 1-integrin-linked protein kinase. Nature. 379:91-96.
6. Hannigan, G., Troussard, A.A., and Dedhar, S. 2005. Integrin-linked kinase: a cancer therapeutic target unique among its ILK. Nat. Rev. Cancer. 5:51-63.
7. White, D.E., Cardiff, R.D., Dedhar, S., and Muller, W.J. 2001. Mammary epithelial-specific expression of the integrin-linked kinase (ILK) results in the induction of mammary gland hyperplasias and tumors in transgenic mice. Oncogene. 20:7064-7072.
8. Yau, C.Y., Wheeler, J.J., Sutton, K.L., and Hedley, D.W. 2005. Inhibition of integrin-linked kinase by a selective small molecule inhibitor, QLT0254, inhibits the PI3K/PKB/mTOR, Stat3, and FKHR pathways and tumor growth, and enhances gemcitabine-induced apoptosis in human orthotopic primary pancreatic cancer xenografts. Cancer Res. 65:1497-1504.
9. Edwards, L.A., et al. 2008. Suppression of VEGF secretion and changes in glioblastoma multiforme microenvironment by inhibition of integrin-linked kinase (ILK). Mol. Cancer Ther. 7:59-70.
10. Tan, C., et al. 2004. Regulation of tumor angiogenesis by integrin-linked kinase (ILK). Cancer Cell. 5:79-90.
11. Lorenz, K., et al. 2007. Integrin-linked kinase is required for epidermal and hair follicle morphogenesis. J. Cell Biol. 177:501-513.
12. Miller, M.G., et al. 2003. Integrin-linked kinase is a positive mediator of L6 myoblast differentiation. Biochem. Biophys. Res. Commun. 310:796-803.
13. Haase, M., et al. 2008. Expression of Integrin-linked Kinase Is Increased in Differentiated Cells. J. Histochem. Cytochem. 56:819-829.
14. Cordes, N. 2004. Overexpression of hyperactive integrin-linked kinase leads to increased cellular radiosensitivity. Cancer Res. 64:5683-5692.
15. Eke, I., et al. 2007. Pharmacological inhibition of EGFR tyrosine kinase affects ILK-mediated cellular radiosensitization in vitro. Int. J. Radiat. Biol. 83:793-802.
16. Hess, F., Estrugo, D., Fischer, A., Belka, C., and Cordes, N. 2007. Integrin-linked kinase interacts with caspase-9 and -8 in an adhesion-dependent manner for promoting radiation-induced apoptosis in human leukemia cells. Oncogene. 26:1372-1384.
17. Chen, P., Shen, W.Z., and Karnik, P. 2004. Suppression of malignant growth of human breast cancer cells by ectopic expression of integrin-linked kinase. Int. J. Cancer. 111:881-891.
18. Shaulian, E., and Karin, M. 2002. AP-1 as a regulator of cell life and death. Nat. Cell Biol. 4:E131-E136.
19. Huang, S., et al. 2003. Sustained activation of the JNK cascade and rapamycin-induced apoptosis are suppressed by p53/p21(Cip1). Mol. Cell. 11:1491-1501.
20. Huang, S., et al. 2004. Inhibition of mammalian target of rapamycin activates apoptosis signal-regulating kinase 1 signaling by suppressing protein phosphatase 5 activity. J. Biol. Chem. 279:36490-36496.
21. Ostrovsky, O., Bengal, E., and Aronheim, A. 2002. Induction of terminal differentiation by the c-Jun dimerization protein JDP2 in C2 myoblasts and rhabdomyosarcoma cells. J. Biol. Chem. 277:40043-40054.
22. Mauro, A., et al. 2002. PKCalpha-mediated ERK, JNK and p38 activation regulates the myogenic program in human rhabdomyosarcoma cells. J. Cell Sci. 115:3587-3599.
23. Perdiguero, E., Ruiz-Bonilla, V., Serrano, A.L., and Munoz-Canoves, P. 2007. Genetic deficiency of p38alpha reveals its critical role in myoblast cell cycle exit: the p38alpha-JNK connection. Cell Cycle. 6:1298-1303.
24. Lehtinen, S.K., Rahkila, P., Helenius, M., Korhonen, P., and Salminen, A. 1996. Down-regulation of transcription factors AP-1, Sp-1, and NF-kappa B precedes myocyte differentiation. Biochem. Biophys. Res. Commun. 229:36-43.
25. Quelo, I., Gauthier, C., Hannigan, G.E., Dedhar, S., and St-Arnaud, R. 2004. Integrin-linked kinase regulates the nuclear entry of the c-Jun coactivator alpha-NAC and its coactivation potency. J. Biol. Chem. 279:43893-43899.
26. Tamura, S., et al. 2006. PP2C family members play key roles in regulation of cell survival and apoptosis. Cancer Sci. 97:563-567.
27. Aoyagi, Y., Fujita, N., and Tsuruo, T. 2005. Stabilization of integrin-linked kinase by binding to Hsp90. Biochem. Biophys. Res. Commun. 331:1061-1068.
28. Wan, X., and Helman, L.J. 2003. Levels of PTEN protein modulate Akt phosphorylation on serine 473, but not on threonine 308, in IGF-II- overexpressing rhabdomyosarcomas cells. Oncogene. 22:8205-8211.
29. Chung, D.H., et al. 1998. ILK (beta1-integrin-linked protein kinase): a novel immunohistochemical marker for Ewing's sarcoma and primitive neuroectodermal tumour. Virchows Arch. 433:113-117.
30. Persad, S., et al. 2001. Regulation of protein kinase B/Akt-serine 473 phosphorylation by integrin-linked kinase: critical roles for kinase activity and amino acids arginine 211 and serine 343. J. Biol. Chem. 276:27462-27469.
31. Ren, Y.X., et al. 2008. Mouse mesenchymal stem cells expressing PAX-FKHR form alveolar rhabdomyosarcomas by cooperating with secondary mutations. Cancer Res. 68:6587-6597.
32. Delcommenne, M., et al. 1998. Phosphoinositide-3-OH kinase-dependent regulation of glycogen synthase kinase 3 and protein kinase B/AKT by the integrin-linked kinase. Proc. Natl. Acad. Sci. U. S. A. 95:11211-11216.
33. Persad, S., et al. 2000. Inhibition of integrin-linked kinase (ILK) suppresses activation of protein kinase B/Akt and induces cell cycle arrest and apoptosis of PTEN-mutant prostate cancer cells. Proc. Natl. Acad. Sci. U. S. A. 97:3207-3212.
34. Zhang, Y., et al. 2006. Involvement of integrin-linked kinase in carbon tetrachloride-induced hepatic fibrosis in rats. Hepatology. 44:612-622.
35. Leung-Hagesteijn, C., et al. 2005. Integrin-linked kinase mediates bone morphogenetic protein 7-dependent renal epithelial cell morphogenesis. Mol. Cell. Biol. 25:3648-3657.
36. Gupta, S., et al. 1996. Selective interaction of JNK protein kinase isoforms with transcription factors. EMBO J. 15:2760-2770.
37. Baker, S.J., et al. 1989. Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas. Science. 244:217-221.
38. Besson, A., et al. 2007. Discovery of an oncogenic activity in p27Kip1 that causes stem cell expansion and a multiple tumor phenotype. Genes Dev. 21:1731-1746.
39. Yokoyama, A., and Cleary, M.L. 2008. Menin critically links MLL proteins with LEDGF on cancer-associated target genes. Cancer Cell. 14:36-46.
40. de la Iglesia, N., et al. 2008. Identification of a PTEN-regulated STAT3 brain tumor suppressor pathway. Genes Dev. 22:449-462.
41. De Giovanni, C., et al. 1993. Uncoupling of growth inhibition and differentiation in dexamethasone-treated human rhabdomyosarcoma cells. Br. J. Cancer. 67:674-679.
42. Dos Santos, N., et al. 2007. Urokinase-type Plasminogen Activator (uPA) is inhibited with QLT0267 a small molecule targeting Integrin-linked Kinase (ILK). Translational Oncogenomics. 2:67-79.
43. Mongroo, P.S., et al. 2004. Beta-parvin inhibits integrin-linked kinase signaling and is downregulated in breast cancer. Oncogene. 23:8959-8970.
44. Schmittgen, T.D., and Livak, K.J. 2008. Analyzing real-time PCR data by the comparative C(T) method. Nat. Protoc. 3:1101-1108.
45. Somers, G.R., et al. 2006. Pediatric undifferentiated sarcoma of the soft tissues: a clinicopathologic study. Pediatr. Dev. Pathol. 9:132-142.
46. Greenberg, J.A., Somme, S., Russnes, H.E., Durbin, A.D., and Malkin, D. 2008. The estrogen receptor pathway in rhabdomyosarcoma: a role for estrogen receptor-beta in proliferation and response to the antiestrogen 4′OH-tamoxifen. Cancer Res. 68:3476-3485.